Vitamin D and the cardiovascular system

Osteoporosis International

Volumn 24, Issue 8, 2013, Pages 2167-2180

  Beveridge, L A ^a   Witham, M D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Blood pressure; Calcium; Cardiovascular; Diabetes; Endothelium; Vitamin D

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM; CHOLESTEROL; COLECALCIFEROL; CYTOKINE; DRUG METABOLITE; ERGOCALCIFEROL; GLUCOSE; INSULIN; LIPID; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; VASCULOTROPIN; VITAMIN D; VITAMIN D RECEPTOR;

ARTERIAL STIFFNESS; BLOOD PRESSURE; BLOOD VESSEL CALCIFICATION; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE MARKER; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTERVENTION STUDY; LIPID BLOOD LEVEL; META ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE DRUG DOSE; VITAMIN SUPPLEMENTATION;

CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84880278796     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2281-1     Document Type: Review

References (112)

1. Jones G, Strugnell SA, DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. Physiol Rev 78:1193-1231
2. Jean G, Terrat JC, Vanel T et al (2008) Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 110:c58-c65
3. 3 into its active metabolite. Biochem Biophys Res Commun 349:209-213
4. Norman AW (2008) From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88:491S-499S
5. Bischoff-Ferrari HA, Giovannucci E, Willett WC et al (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18-28
6. Haussler MR, Jurutka PW, Mizwicki M et al (2011) Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 25:543-559
7. DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80:1689S-1696S
8. Li YC, Kong J, Wei M et al (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238
9. Tomaschitz A, Pilz S, Ritz E et al (2010) Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 411:1354-1360
10. Forman JP, Williams JS, Fisher ND (2010) Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55:1283-1288
11. 3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. J Clin Endocrinol Metab 97:2456-2465
12. Simpson RU, Hershey SH, Nibbelink KA (2007) Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 103:521-524
13. Green JJ, Robinson DA, Wilson GE et al (2006) Calcitriol modulation of cardiac contractile performance via protein kinase C. J Mol Cell Cardiol 41:350-359
14. Lehto S, Niskanen L, Suhonen M et al (1996) Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16:978-983
15. Watson KE, Abrolat ML, Malone LL et al (1997) Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96:1755-1760
16. 3 plus nicotine. J Vasc Res 34:386-398
17. Demer LL, Tintut Y (2008) Vascular calcification: pathobiology of a multifaceted disease. Circulation 117:2938-2948
18. Hruska KA, Mathew S, Saab G (2005) Bone morphogenetic proteins in vascular calcification. Circ Res 97:105-114
19. Saleh FN, Schirmer H, Sundsfjord J et al (2003) Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24:2054-2060
20. Kosch M, Hausberg M, Vormbrock K et al (2000) Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 47:813-818
21. Kestenbaum B, Katz R, de Boer I et al (2011) Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 58:1433-1441
22. Molinari C, Uberti F, Grossini E et al (2011) 1 Alpha,25- dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cell Physiol Biochem 27:661-668
23. 3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 204:85-89
24. Grundmann M, Haidar M, Placzko S et al (2012) Vitamin D improves the angiogenic properties of endothelial progenitor cells. Am J Physiol Cell Physiol. doi: 10.1152/ajpcell.00030.2012
25. 3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial cells. Cardiology 118:107-115
26. Aihara K, Azuma H, Akaike M et al (2004) Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 279:35798-35802
27. Pitocco D, Crino A, Di Stasio E et al (2006) The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 23:920-923
28. 3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 57:258-261
29. Norman AW, Frankel JB, Heldt AM (1980) Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209:823-825
30. Fadda GZ, Akmal M, Lipson LG et al (1990) Direct effect of parathyroid hormone on insulin secretion from pancreatic islets. Am J Physiol 258:E975-E984
31. Kolb H, Mandrup-Poulsen T (2005) An immune origin of type 2 diabetes? Diabetologia 48:1038-1050
32. Schleithoff SS, Zittermann A, Tenderich G et al (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83:754-759
33. Equils O, Naiki Y, Shapiro AM et al (2006) 1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol 143:58-64
34. Jablonski KL, Chonchol M, Pierce GL (2011) 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 57:63-69
35. Reid D, Toole BJ, Knox S et al (2011) The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr 93:1006-1011
36. Scragg R, Sowers M, Bell C (2007) Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 20:713-719
37. Fraser A, Williams D, Lawlor DA (2010) Associations of serum 25-hydroxyvitamin D, parathyroid hormone and calcium with cardiovascular risk factors: analysis of 3 NHANES cycles (2001-2006). PLoS One 5:e13882
38. Martins D, Wolf M, Pan D et al (2007) Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167:1159-1165
39. Hypponen E, Boucher BJ, Berry DJ et al (2008) 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 57:298-305
40. Ganji V, Zhang X, Shaikh N et al (2011) Serum 25-hydroxyvitamin D concentrations are associated with prevalence of metabolic syndrome and various cardiometabolic risk factors in US children and adolescents based on assay-adjusted serum 25-hydroxyvitamin D data from NHANES 2001-2006. Am J Clin Nutr 94:225-233
41. Al Mheid I, Patel R, Murrow J et al (2011) Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 58:186-192
42. Yiu YF, Chan YH, Yiu KH et al (2011) Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J Clin Endocrinol Metab 96:E830-E835
43. Poole KE, Loveridge N, Barker PJ et al (2006) Reduced vitamin D in acute stroke. Stroke 37:243-245
44. Zittermann A, Schleithoff SS, Tenderich G (2003) Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 41:105-112
45. 3 levels: a community-based study. Int J Epidemiol 19:559-563
46. 3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 29:722-724
47. Forman JP, Giovannucci E, Holmes MD et al (2007) Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49:1063-1069
48. Forman JP, Curhan GC, Taylor EN (2008) Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 52:828-832
49. Pittas AG, Chung M, Trikalinos T et al (2010) Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 152:307-314
50. Burgaz A, Orsini N, Larsson SC (2011) Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens 29:636-645
51. Margolis KL, Martin LW, Ray RM et al (2012) A prospective study of serum 25-hydroxyvitamin D levels, blood pressure, and incident hypertension in postmenopausal women. Am J Epidemiol 175:22-32
52. Pittas AG, Sun Q, Manson JE et al (2010) Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care 33:2021-2023
53. Pittas AG, Nelson J, Mitri J et al (2012) Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the Diabetes Prevention Program. Diabetes Care 35:565-573
54. Mitri J, Muraru MD, Pittas AG (2011) Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 65:1005-1015
55. Forouhi NG, Ye Z, Rickard AP et al (2012) Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia 55:2173-2182
56. Parker J, Hashmi O, Dutton D et al (2010) Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 65:225-236
57. Wang TJ, Pencina MJ, Booth SL et al (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503-511
58. Thomas GN, Hartaigh B, Bosch JA et al (2012) Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Diabetes Care 35:1158-1164
59. Sun Q, Pan A, Hu FB (2012) 25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis. Stroke 43:1470-1477
60. Brondum-Jacobsen P, Nordestgaard BG, Schnohr P et al (2012) 25-Hydroxyvitamin D and symptomatic ischemic stroke: An Original Study and Meta-Analysis. Ann Neurol. doi: 10.1002/ana.23738
61. Chowdhury R, Stevens S, Ward H et al (2012) Circulating vitamin D, calcium and risk of cerebrovascular disease: a systematic review and meta-analysis. Eur J Epidemiol 27:581-591
62. Brondum-Jacobsen P, Benn M, Jensen GB et al (2012) 25-Hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol 32:2794-2802
63. Scragg R (2011) Vitamin D and public health: an overview of recent research on common diseases and mortality in adulthood. Public Health Nutr 14:1515-1532
64. Grandi NC, Breitling LP, Brenner H (2010) Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med 51:228-233
65. Pilz S, Iodice S, Zittermann A (2011) Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 58:374-382
66. Witham MD, Crighton LJ, Gillespie ND (2010) The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 3:195-201
67. Shane E, Mancini D, Aaronson K et al (1997) Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 103:197-207
68. Pilz S, Marz W, Wellnitz B et al (2008) Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93:3927-3935
69. Boxer RS, Kenny AM, Cheruvu VK et al (2010) Serum 25-hydroxyvitamin D concentration is associated with functional capacity in older adults with heart failure. Am Heart J 160:893-899
70. Gotsman I, Shauer A, Zwas DR et al (2012) Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail 14:357-366
71. Anderson JL, May HT, Horne BD et al (2010) Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 106:963-968
72. Rienstra M, Cheng S, Larson MG et al (2011) Vitamin D status is not related to development of atrial fibrillation in the community. Am Heart J 162:538-541
73. Smith MB, May HT, Blair TL et al (2011) Vitamin D excess is significantly associated with risk of atrial fibrillation. Circulation 124:A14699
74. Isaia G, Giorgino R, Rini GB et al (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 14:577-582
75. Oplander C, Volkmar CM, Paunel-Gorgulu A et al (2009) Whole body UVA irradiation lowers systemic blood pressure by release of nitric oxide from intracutaneous photolabile nitric oxide derivates. Circ Res 105:1031-1040
76. 3 supplementation Has no effect on conventional cardiovascular risk factors. a parallel-group, double-blind, placebo-controlled RCT. J Clin Endocrinol Metab 97:3557-3568
77. Carter GD (2012) 25-hydroxyvitamin D: a difficult analyte. Clin Chem 58:486-488
78. Witham MD, Nadir MA, Struthers AD (2009) Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens 27:1948-1954
79. Wu SH, Ho SC, Zhong L et al (2010) Effects of vitamin D supplementation on blood pressure. South Med J 103:729-737
80. Larsen T, Mose FH, Bech JN (2012) Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am J Hypertens 25:1215-1222
81. Thadhani R, Appelbaum E, Pritchett Y et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674-684
82. Wang H, Xia N, Yang Y (2012) Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis 11:42
83. Perez-Castrillon JL, Vega G, Abad L et al (2007) Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99:903-905
84. Rejnmark L, Vestergaard P, Heickendorff L (2010) Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol 2010:957174
85. Yavuz B, Ertugrul DT, Cil H et al (2009) Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 23:295-299
86. Schwartz JB (2009) Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther 85:198-203
87. Witham MD, Dove FJ, Khan F et al (2012) Effects of vitamin D supplementation on markers of vascular function after myocardial infarction - a randomised controlled trial. Int J Cardiol. doi: 10.1016/j.ijcard.2012.03.054
88. Witham MD, Dove FJ, Dryburgh M et al (2010) The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 53:2112-2119
89. Witham MD, Dove FJ, Sugden JA et al (2012) The effect of vitamin D replacement on markers of vascular health in stroke patients - a randomised controlled trial. Nutr Metab Cardiovasc Dis 22:864-870
90. Tarcin O, Yavuz DG, Ozben B et al (2009) Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 94:4023-4030
91. Sugden JA, Davies JI, Witham MD et al (2008) Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diab Med 25:320-325
92. 3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens 24:557-562
93. Hsia J, Heiss G, Ren H et al (2007) Calcium/vitamin D supplementation and cardiovascular events. Circulation 115:846-854
94. de Boer IH, Tinker LF, Connelly S et al (2008) Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 31:701-707
95. 3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469
96. Elamin MB, Abu Elnour NO, Elamin KB et al (2011) Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 96:1931-1942
97. Wang L, Manson JE, Song Y et al (2010) Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 152:315-323
98. Chlebowski RT, Johnson KC, Kooperberg C et al (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581-1591
99. Marckmann P, Agerskov H, Thineshkumar S et al (2012) Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 27:3523-3531
100. Kandula P, Dobre M, Schold JD et al (2011) Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 6:50-62
101. Palmer SC, McGregor DO, Macaskill P (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147:840-853
102. de Zeeuw D, Agarwal R, Amdahl M et al (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543-1551
103. Cheng J, Zhang W, Zhang X et al (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 7:391-400
104. George PS, Pearson ER, Witham MD (2012) Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med 29:e142-e150
105. Avenell A, Cook JA, Maclennan GS et al (2009) Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 38:606-609
106. 3 levels are elevated in South Indian patients with ischemic heart disease. Eur J Epidemiol 17:567-571
107. Durup D, Jorgensen HL, Christensen J (2012) A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab 97:2644-2652
108. de Boer IH, Levin G, Robinson-Cohen C et al (2012) Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study. Ann Intern Med 156:627-634
109. Bolland MJ, Avenell A, Baron JA et al (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691
110. Avenell A, Maclennan GS, Jenkinson DJ et al (2012) Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 97:614-622
111. Bolland MJ, Grey A, Avenell A (2011) Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 342:d2040
112. Rejnmark L, Avenell A, Masud T et al (2012) Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab 97:2670-2681